Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. - Wikidata - wikimedia - TriplyDB

Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape.

Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape.

http://www.wikidata.org/entity/Q34194706

about

Clinical Development of the E75 Vaccine in Breast Cancer Mechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It CD8⁺ T Cell-Independent Immune-Mediated Mechanisms of Anti-Tumor Activity Myeloid-derived suppressor cells and anti-tumor T cells: a complex relationship Tumor antigen-specific monoclonal antibodies and induction of T-cell immunity Monoclonal antibodies for the treatment of cancer Cetuximab Reconstitutes Pro-Inflammatory Cytokine Secretions and Tumor-Infiltrating Capabilities of sMICA-Inhibited NK Cells in HNSCC Tumor Spheroids.Induction of Wnt-inducible signaling protein-1 correlates with invasive breast cancer oncogenesis and reduced type 1 cell-mediated cytotoxic immunity: a retrospective study Antibody Therapies in Cancer.Immunotherapy as a Potential Treatment for Chordoma: a Review.IgE-based immunotherapy of cancer: challenges and chances.Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Novel Linear Peptides with High Affinity to αvβ3 Integrin for Precise Tumor Identification.Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients A novel approach to biomarker discovery in head and neck cancer using an autoantibody signature.Targeting CD137 enhances the efficacy of cetuximab.Potent Therapeutic Activity Against Peritoneal Dissemination and Malignant Ascites by the Novel Anti-Folate Receptor Alpha Antibody KHK2805.The study on newly developed McAb NJ001 specific to non-small cell lung cancer and its biological characteristics MRl of prostate cancer antigen expression for diagnosis and immunotherapy.A first-in-human study of the anti-α5β1 integrin monoclonal antibody PF-04605412 administered intravenously to patients with advanced solid tumors.Human anti-CCR4 minibody gene transfer for the treatment of cutaneous T-cell lymphoma.The immune response to tumors as a tool toward immunotherapy.Selective role of mevalonate pathway in regulating perforin but not FasL and TNFalpha release in human Natural Killer cells Immune biomarkers of anti-EGFR monoclonal antibody therapy Control of advanced cancer: the road to chronicity.Human xeno-autoantibodies against a non-human sialic acid serve as novel serum biomarkers and immunotherapeutics in cancer.Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2.TLR2 agonist PSK activates human NK cells and enhances the antitumor effect of HER2-targeted monoclonal antibody therapy.CTLA-4⁺ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis.Metronomic cyclophosphamide eradicates large implanted GL261 gliomas by activating antitumor Cd8(+) T-cell responses and immune memory Victory and defeat in the induction of a therapeutic response through vaccine therapy for human and canine brain tumors: a review of the state of the art.Economic evaluation of therapeutic cancer vaccines and immunotherapy: a systematic review.Whole cell vaccines--past progress and future strategies.Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone Immunology and Immunotherapy of Head and Neck Cancer Serum biomarkers as potential predictors of antitumor activity of cetuximab-containing therapy for locally advanced head and neck cancer High plasma fibrinogen is correlated with poor response to trastuzumab treatment in HER2 positive breast cancer.Cancer immunotherapy: Progress and challenges in the clinical setting.Hidden immunotherapy targets challenge dogma

P2860

Q26745440-AD093E6A-F40D-4EC4-8A3F-712F5E50F42A Q26752780-BCE745AD-269D-48D6-A39C-C14F6B2855E9 Q26782520-97880B7D-3281-4A99-847F-484A1D81CDF4 Q27000087-D4471FC3-F983-4FBA-917B-96C688952856 Q27009908-18B2C5F1-F719-403A-A020-36407F138F2C Q27025966-3BEAD878-B481-4D97-B178-D86CEB3484E8 Q27329648-1A12308E-399C-4C44-8D44-F0E03BA3BE4F Q28538654-5C516F43-4943-48C6-A9CF-480255055CAC Q31104000-36A2BBBD-B86C-4F23-BD56-9D4D15CE33B5 Q33276143-090783BE-FA15-480B-B026-C69FC627A623 Q33619979-FBDD33BA-B844-497A-BCF5-4AD273712406 Q33644305-0C78A2CB-452D-4C4B-9BCB-1FF51DCF8D47 Q33650470-AAD83D98-34D0-440E-B7F7-31FF2FD3C4AF Q33703084-D3E32D60-0BAB-46C0-8A2E-5D01C46E2CD0 Q33809528-AF6EFEE8-D21B-4EB6-90A5-C706C3BE6532 Q33851750-A9B0F874-8D8F-4A21-8593-C3962BE6C72F Q33872482-FBC9990A-DCE2-4E50-9EB1-999CC2AABBF0 Q33900573-85B6192D-7F24-42A7-9E93-FDECBF7F1EB5 Q34221272-E871D310-284C-4AE1-87AC-CB032B8EC3B6 Q34325715-0E815828-D645-4A02-B075-15BD412CAA03 Q34403364-811E6F5A-D3EC-49B6-9C8A-8655B9F06438 Q34413695-260436BB-836B-4C04-8C52-27D87E19495C Q34634545-402977B5-ECE7-4641-9171-CA13A8684F52 Q34717893-4794B3C1-0A3C-4390-863E-48FE8DCC1672 Q34723594-696465BC-FE85-4184-BA73-DDF9E99939B8 Q34874471-7DA63839-D8BF-4FDB-82C4-322C4ABB7582 Q34900010-4CBB7523-44C5-42AC-B0FB-F42C4A9CEAF1 Q35437978-6207E321-3347-4BB1-A683-8ABC6E972251 Q35510560-79BF1564-DDA5-4D3E-A346-1B042075484D Q35674757-DD8E6738-4E77-41C0-85B4-56FF997A1AD6 Q35799297-DE873452-6168-42CD-B698-215A3C8B6D4A Q35799695-95C06425-ADC0-4486-8925-F111770368F6 Q35886444-8D93B5AC-8879-4EF2-AF53-AA3801328868 Q35975381-00792A2E-37C6-4729-A065-3462187321B2 Q36006440-9930F5B1-FACF-4253-B8DB-64E9DA1EE03B Q36100837-513DCF97-D59E-428F-BB1B-5BACCE97954D Q36109779-DFB6B0F1-BC38-48D4-900C-310D012B60A2 Q36152165-7D542F84-07AC-4991-8A63-C91DB77D6071 Q36184314-3503FD39-A189-4EE8-A39D-220B6203C4C7 Q36184951-2771F127-5D44-4203-AB25-174B663D21BB

P2860

Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape.

http://www.wikidata.org/entity/Q34194706

description

2010 nî lūn-bûn

@nan

2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Tumor antigen-targeted, monocl ...... ar immunity, and immunoescape.

@ast

Tumor antigen-targeted, monocl ...... ar immunity, and immunoescape.

@en

Tumor antigen-targeted, monocl ...... ar immunity, and immunoescape.

@nl

type

label

Tumor antigen-targeted, monocl ...... ar immunity, and immunoescape.

@ast

Tumor antigen-targeted, monocl ...... ar immunity, and immunoescape.

@en

Tumor antigen-targeted, monocl ...... ar immunity, and immunoescape.

@nl

prefLabel

Tumor antigen-targeted, monocl ...... ar immunity, and immunoescape.

@ast

Tumor antigen-targeted, monocl ...... ar immunity, and immunoescape.

@en

Tumor antigen-targeted, monocl ...... ar immunity, and immunoescape.

@nl

P1433

Q34194706-A65E200B-2657-40FC-A3C1-A8C56C43CE29

P1476

Q34194706-32D6027D-8445-4EF4-8D9A-DDEAD7F0D4CE

P2093

Q34194706-2C348BDF-62C5-4E9F-A8A4-5ED098305060

Q34194706-8E0AA1EE-3E59-4E4E-BEEC-C0860CF10CA9

P2860

Q34194706-01A896B9-8A29-4D99-8767-6BC4E651626A

Q34194706-02AF1B27-38E3-446E-A7B1-2ACF4CD84915

Q34194706-04535852-8ABB-4DBA-AA95-38A53699FA35

Q34194706-050E91CB-67F6-4CFD-9E41-4B85B1BEA1D8

Q34194706-06F3EABA-88F6-49FD-B278-E4CF87C043A1

Q34194706-0878E48B-A0C2-4A29-B974-583D8E8DAF40

Q34194706-0990AE0A-F7B1-4DCB-8539-7042178BE1B2

Q34194706-0E2D9CCB-54B8-40C3-8A8B-D9A91E44AB24

Q34194706-0FC9490D-1594-4268-BF80-4FF70A36B1DE

Q34194706-136772CA-FB35-40CB-9497-F3B101C070A0

P304

Q34194706-00CA3E3B-EFE8-41A9-A6AB-D39734894850

P31

Q34194706-9CDF9F9E-87AB-40EB-BEC1-36831FBAC803

P356

Q34194706-B3A9A4C1-5E0C-4735-AFFA-7A9215998AD9

P407

Q34194706-7C579030-1D8B-4926-804E-AA7E556D45B7

P433

Q34194706-BA7D4F87-C4B6-48C3-BB49-3894DA1A5898

P478

Q34194706-5432314A-BB4E-4FA0-BCA2-C4CAB383A9C3

P50

Q34194706-3862491B-268F-4768-8B1B-436F2187719D

P577

Q34194706-D209131B-CA9E-4D52-BEDB-495EC38762ED

P5875

Q34194706-48C085A6-BF1B-4E71-8839-6312B8AB4C1F

P698

Q34194706-FB91920F-DF14-497A-8B64-160BAA37FF67

P921

Q34194706-21E3ADCB-4E60-4B17-9135-FB95E5BF2C6A

Q34194706-33FC8214-97AA-4FBF-9279-15E0D787A069

P932

Q34194706-E10FC6DC-5995-431B-9B47-5734196156C9

P356

JCO.2009.27.6360

P1433

Journal of Clinical Oncology

P1476

Tumor antigen-targeted, monocl ...... ar immunity, and immunoescape.

@en

P2093

Robert L Ferris

http://www.w3.org/2001/XMLSchema#string

Soldano Ferrone

http://www.w3.org/2001/XMLSchema#string

P2860

Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity

Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas.

Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival.

MECT1-MAML2 fusion transcript defines a favorable subset of mucoepidermoid carcinoma

Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor rec

Cross-talk between G protein-coupled receptor and epidermal growth factor receptor signaling pathways contributes to growth and invasion of head and neck squamous cell carcinoma

The mannose receptor mediates uptake of soluble but not of cell-associated antigen for cross-presentation

IgG Fc receptors

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis.

P304

4390-4399

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2009.27.6360

http://www.w3.org/2001/XMLSchema#string

P407

P433

28

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

Elizabeth Jaffee

P577

2010-08-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45583523

http://www.w3.org/2001/XMLSchema#string

P698

20697078

http://www.w3.org/2001/XMLSchema#string

P921

P932

2954137

http://www.w3.org/2001/XMLSchema#string